BIIB vs RVTY
Biogen vs Revvity — AI-powered side-by-side comparison
| Metric | BIIB | RVTY |
|---|
| AI Score |
67
|
72
|
| Price |
$208.02
|
$114.66
|
| P/E Ratio |
36.61×
|
54.60×
|
| ROE |
7.1%
|
3.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.7%
|
52.1%
|
| Debt / Equity |
0.44×
|
0.46×
|
| Dividend Yield |
0.0%
|
0.2%
|
| RSI (14) |
56.7
|
57.8
|
| Beta |
0.158
|
1.091
|
| Expected Upside |
+5.2%
|
+1.3%
|
AI Committee View
Current Innellis committee reasoning for BIIB versus RVTY.
RVTY leads by 5 points.
RVTY scores 72/100 (Buy) versus BIIB at 67/100 (Buy).
BIIB Committee View
80% agreement
5 analysts
The primary driver is news sentiment is positive (+0.42 across 47 articles, 14d). The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
RVTY Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Risk/reward is unfavorable: 27.2% downside vs 1.3% upside.